BioMerieux (EYWN.MU,BIM.PA) reported first quarter consolidated sales of 984 million euros, down 10.4% as reported from last year. On an organic basis, sales were down 3.9%. The company said the decline was due to a weaker respiratory season compared with the exceptionally strong epidemiology in the first quarter of prior year and a slow start of the year in instruments sales in a soft market for new installations.
The company revised its 2026 full-year guidance. It now projects: annual sales to grow organically between 3% to 5%, revised form prior guidance of beween 5% and 7%. Annual Contributive operating income before non-recurring items or CEBIT is expected to grow organically between 0% and 10%, updated from previous guidance of of at least 10%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.